KYORIN Co., Ltd.
5 Kanda Surugadai, 2-chome, Chiyoda-ku, TokyoTSE Code: 4569 (First Section)

Results of Analysis of the OASIS Study, a Large-Scale Health-Related QOL Study inPatients with Chronic Cerebral Infarction
Tokyo, Japan—Feb. 21, 2008—Having completed the OASIS Study,*1 Japan’s firstlarge-scale study with respect to health-related quality of life (below, “health-relatedQOL”*) in Chronic Cerebral Infarction , Kyorin Pharmaceutical Co., Ltd. (Tokyo,President: Ikuo Ogihara), a subsidiary of Kyorin Co., Ltd., presented the study results atthe International Stroke Conference 2008 at New Orleans, Louisiana, USA on February
20 local time.
*Health-Related QOL: Quality of life (QOL) used in the assessment of medical care, defined as a concept
limited to issues stemming from personal health and not encompassing financial matters or other factors
arising from the social environment

The OASIS Study aimed at 1) assessing health-related QOL and 2) investigating therelationship between health-related QOL and dizziness in patients with chronic
cerebral infarction in Japan. This epidemiological study was performed at 162
institutions from July 2005 to June 2007, with Yukito Shinohara MD, PhD, (a directorof Federation of National Public Service Personnel Mutual Aid Associations Tachikawa
Hospital and chair of The Japan Stroke Society) chairing the study. The study
population consisted of 2069 Japanese patients with chronic cerebral infarction.
Verification of health-related QOL relied on the SF-36v2*2 score, an index usedworldwide, in addition to a survey covering a range patient information.
A summary of the presentation follows:*Japanese patients with chronic cerebral infarction exhibited a low
health-related QOL score, as did their counterparts in other countries. The results
suggested that patients require therapies oriented to health-related QOL.
*The determination of health-related QOL in Japanese patients with chronic
cerebral infarction with SF-36v2 revealed a number of characteristics:- A close relationship was recognized between the severity of cerebral

infarction and the physical health-related QOL score.
- Female with chronic cerebral infarction patients exhibited an inferior degreeof physical and mental health in comparison with male patients.
*Japanese patients are more prone to dizziness as a subjective symptom. It wasclarified that treatment of dizziness was important, since the symptom adversely
affected health-related QOL.
Kyorin Pharmaceutical Co., Ltd. will clarify details of health-related QOL in Japanesepatients with cerebral infarction by means of a sub-analysis of the study results and will
also verify the significance of the use of Ketas (common name: ibudilast), a drug for
cerebrovascular disorders. The results will be reported at relevant academic meetings inJapan and overseas. Kyorin Pharmaceutical Co., Ltd. will continue to contribute to thetreatment of chronic cerebral infarction from the perspective of health-related QOL.
*1: OASIS Study: Outcome Assessment using SF-36v2 in stroke patients*2: SF-36v2: MOS Short-Form 36-Item Health Survey. A scientifically reliable and valid scale fordetermining health-related QOL. SF-36v2 is characterized by a structure based on a common concept ofhealth-related QOL for everyone, without being limited to specific illnesses. It enables the determinationof health-related QOL, both for patients having different illnesses and generally healthy people.
Following a comprehensive discussion from the stage of the construction of the concept throughcomputational-psychological verification, SF-36v2 is used widely around the world, having beentranslated into over 60 languages.

OASIS Study Summary
Subjects: 2069 patients with cerebral infarction more than 1 month after onset
Period: July 2005 to June 2007
Observation time: Enrollment, Week 8 and Week 24
Study type: Epidemiological study (based on observation)
Study items: 1) Backgrounds (e.g., symptoms, presence of rehabilitation andconcomitant medication)
2) Effects of therapy (for dizziness, depression and others)3) QOL survey (with SF-36v2)

KetasKetas (common name: ibudilast) is a drug for asthma and cerebrovascular disorders
developed internally by Kyorin Pharmaceutical Co., Ltd., which released it in 1989. In
the treatment of cerebrovascular disorders, the drug is indicated for dizziness caused bychronic cerebral circulatory disorders accompanying the aftereffects of cerebral
infarction. The usefulness has been shown in re-evaluation in a placebo-controlled
double blind comparative study.
Cerebral infarction
Cerebral infarction is a variation of stroke. It hinders blood circulation because brain
blood vessels are blocked or narrowed. Stroke is the third leading cause of death inJapan, following cancer and heart disease. According to statistics by the Ministry ofHealth, Labour and Welfare, around 1,500,000 patients are hospitalized or attending
hospital because of stroke (there are about 1,130,000 patients with chronic cerebral
infarction). The average number of days of hospitalization is longer for stroke patients
than for patients presenting with any other diseases or disorders. Stroke is a verysignificant disease since it has the highest mortality rate of all afflictions and once itoccurs, it imposes a heavy physical and economic burden on the patient and thepatient’s family.
For more information, please contact:
KYORIN Co., Ltd.
Management Planning Department
Phone: 03-3293-3414